Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 17,845 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Substance Use, HIV/AIDS, Older Adults, Behavioral Intervention, Infectious Disease
Interventions: Psycho-educational content (5 Minutes), Readiness Assessment (10 minutes), Goal-Setting (5 minutes), Identifying and prioritizing needs (5 minutes), Explanation of Peer Navigator and Session wrap (5 minutes); Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida • Lake City, Florida

Conditions: Head and Neck Cancer, Neck Dissection, Postoperative Complications
Interventions: Porcine Extracellular Matrix Nerve Wrap (AxoGuard Nerve Protector™); Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type2 Diabetes, Dyslipidemia
Interventions: K-877, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 242
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more

Conditions: Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions: AP301, AP301 Low Dose; Drug
Lead sponsor: Alebund Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more

Conditions: Mild Cognitive Impairment
Interventions: Structured exercise, Health Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder
Interventions: Placebo, lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 19
States / cities: Burbank, California • Loma Linda, California • San Diego, California + 16 more

Conditions: Pulmonary Fibrosis, Anxiety
Interventions: Digital cognitive behavioral therapy; Device
Lead sponsor: Vicore Pharma AB; Industry
Eligibility: 22 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: San Francisco, California • Salt Lake City, Utah

Conditions: Critical Illness
Interventions: WFIT; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neonatal Infection, Neonatal Necrotizing Enterocolitis
Interventions: Gloves; Other
Lead sponsor: University of Virginia; Other
Eligibility: Up to 8 Days
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Congenital Heart Defect
Interventions: inhaled nitric oxide (iNO); Drug
Lead sponsor: Ellen Spurrier; Other
Eligibility: 1 Year to 5 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Postoperative Pain, Anxiety Postoperative, Opioid Use
Interventions: Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG, Essence Olfactory Necklace, Bedside Olfaction Device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Joint Home-DM-BAT Intervention, Usual Care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Diabetic Retinopathy
Interventions: Non-mydriatic color fundus photography with the RetinaVue camera, Referral for dilated eye exam with an eye care professional; Diagnostic Test
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions: MemorEM 1000; Device
Lead sponsor: NeuroEM Therapeutics, Inc.; Industry
Eligibility: 63 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pain, Chronic, Opioid Use
Interventions: post-surgical opioid use measured at 1 day and 1 week.; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis
Interventions: ELND002, Placebo; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 17
States / cities: Berkeley, California • Fresno, California • Newport Beach, California + 14 more

Conditions: HIV Disease, Chronic Pain
Interventions: Communication Strategy, Standard of Care; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catheter-Associated Urinary Tract Infection
Interventions: Bactrim, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Cancer, Renal Cell Carcinoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years to 79 Years
Enrollment: 2,424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Detroit, Michigan

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C); Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more

Conditions: Tinea Pedis
Interventions: Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more

Search by objective public record fields.

Feasibility of SBIRT-PN

Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Exercise Training to Improve Cognitive Function

Depression And Bipolar Disorder

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF

Wake Forest Post-ICU Telehealth (WFIT) Program

Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis

The Effects of Inhaled Nitric Oxide After Fontan Operation

Virtual Reality and Olfactory Stimuli Multimodal Intervention to Reduce Post-Operative Pain and Anxiety in Patients Undergoing Cardiothoracic Surgery

Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes

S0820, Adenoma and Second Primary Prevention Trial

RetinaVue Diabetic Screening

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients

Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis